Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes - Anta, L.; Blanco, J. L.; Llibre, J. M.; Garcia, F.; Perez-Elias, M. J.; Aguilera, A.; Perez-Romero, P.; Caballero, E.; Vidal, C.; Canizares, A.; Gutierrez, F.; Dalmau, D.; et al. (Journal of antimicrobial chemotherapy, 2013)
Keywords: Adult; Anti-HIV Agents - pharmacology; Antiretroviral drugs; Drug resistance; Female; Genes; HIV; HIV Infections - virology; HIV Protease - genetics; HIV Protease Inhibitors - pharmacology; HIV Reverse Transcriptase - genetics; HIV-1 - drug effects; HIV-1 - genetics; HIV-1 - isolation & purification; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Male; Mutation, Missense; Polymorphism; Prevalence; Proteases; Reverse Transcriptase Inhibitors - pharmacology; Sequence Analysis, DNA; Spain; Spain; HIV-1 diversity; etravirine; darunavir; drug resistance; tipranavir; rilpivirine